Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Key Points

• To examine the impact of initiating biologics as first-line systemic therapy for psoriasis on clinical outcomes.
• Cohort study design
• Utilized data from the British Association of Dermatologists Biologics and Immunomodulators Register
• Compared outcomes of biologic therapies versus standard stepwise treatments
• Patients on biologics showed significantly better clinical outcomes than those on stepwise approaches
• Findings indicate that earlier use of biologics can lead to improved health for psoriasis patients